Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436)

Katherine L. Nathanson[1,2], Anne-Marie Martin[3], Bradley Wubbenhorst[1], Joel Greshock[3], Richard Letrero[1], Kurt D'Andrea[1], Steven O'Day[4], Jeffrey R. Infante[5], Gerald S. Falchook[6], Hendrik-Tobias Arkenau[10], Michael Millward[11], Michael P. Brown[12], Anna Pavlick[8], Michael A. Davies[7], Bo Ma[9], Robert Gagnon[3], Martin Curtis[9], Peter F. Lebowitz[3], Richard Kefford[13], and Georgina V. Long[13]

Abstract

Purpose: Dabrafenib is a selective inhibitor of V600-mutant BRAF kinase, which recently showed improved progression-free survival (PFS) as compared with dacarbazine, in metastatic melanoma patients. This study examined potential genetic markers associated with response and PFS in the phase I study of dabrafenib.

Experimental Design: Baseline (pretreatment or archival) melanoma samples were evaluated in 41 patients using a custom genotyping melanoma-specific assay, sequencing of *PTEN*, and copy number analysis using multiplex ligation amplification and array-based comparative genomic hybridization. Nine patients had on-treatment and/or progression samples available.

Results: All baseline patient samples had *BRAF*[V600E/K] confirmed. Baseline PTEN loss/mutation was not associated with best overall response to dabrafenib, but it showed a trend for shorter median PFS [18.3 (95% confidence interval, CI, 9.1–24.3) vs. 32.1 weeks (95% CI, 24.1–33), $P = 0.059$]. Higher copy number of *CCND1* ($P = 0.009$) and lower copy number of *CDKN2A* ($P = 0.012$) at baseline were significantly associated with decreased PFS. Although no melanomas had high-level amplification of BRAF, the two patients with progressive disease as their best response had *BRAF* copy gain in their tumors.

Conclusions: Copy number changes in *CDKN2A*, *CCND1*, and mutation/copy number changes in *PTEN* correlated with the duration of PFS in patients treated with dabrafenib. The results suggest that these markers should be considered in the design and interpretation of future trials with selective BRAF inhibitors in advanced melanoma patients. *Clin Cancer Res; 19(17); 4868–78. ©2013 AACR.*

Authors' Affiliations: [1]Department of Medicine, Division of Translational Medicine and Human Genetics; [2]Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia; [3]GlaxoSmithKline, Upper Providence, Pennsylvania; [4]The Angeles Clinic and Research Institute, Los Angeles, California; [5]The Sarah Cannon Research Institute, Nashville, Tennessee; Departments of [6]Investigational Cancer Therapeutics and [7]Melanoma Medical Oncology, MD Anderson Cancer Center, Houston, Texas; [8]New York University, New York City, New York; [9]GlaxoSmithKline, Research Triangle Park, North Carolina; [10]GlaxoSmithKline Medicines Research Unit, Prince of Wales Hospital, Randwick, NSW; [11]Sir Charles Gairdner Hospital, Perth; [12]Cancer Clinical Trials Unit, Royal Adelaide Hospital, and School of Medicine, University of Adelaide, Adelaide; and [13]Melanoma Institute Australia and Westmead Hospital, University of Sydney, Australia

Corresponding Author: Katherine L. Nathanson, 351 BRB 2/3, 421 Curie Blvd., Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104. Phone: 215-573-9840; Fax: 215-573-6298; E-mail: knathans@exchange.upenn.edu

©2013 American Association for Cancer Research.

Introduction

Melanoma is the most lethal form of skin cancer. In the United States, it is estimated that there will be 76,250 new cases and 9,180 deaths related to melanoma in 2012, and the incidence in increasing (1). Melanomas are characterized by a high rate of single-base mutations, as compared to other solid cancer types, associated with an UV light induced signature, as well as a characteristic profile of genomic amplifications and deletions (2, 3). Mutations in *BRAF* are found in ~45% of melanomas (4, 5), the majority of which are at codon 600 and result in constitutive kinase activity of BRAF and subsequent downstream signaling through the MAP kinase pathway (6). Seventy to ninety percent of BRAF mutations are due to the substitution of glutamic acid for valine (V600E mutation; c.1799T>A), and 10% to 30% are due to the substitution with lysine (V600K; refs. 4, 5, 7). Common genomic changes in melanoma include deletion of *PTEN*, and *CDKN2A* and amplifications of *KIT*, *MITF*, *TERT*, *CCND1*, among others (3). *PTEN* deletions are most commonly observed in conjunction with *BRAF* mutations, in approximately 30%, whereas *CDKN2A* mutations are seen across all mutational (*BRAF*/*NRAS*/WT)

American Association for *Cancer Research*

Translational Relevance

Multiple studies have evaluated acquired mutations in melanomas from patients who progress on BRAF inhibitor therapies. This study focuses on pretreatment predictors of outcome when treated with the BRAF inhibitor dabrafenib. Common genetic mutation and genomic aberrations in melanoma were examined, with those in *CDKN2A*, *CCND1*, and *PTEN* found to correlate with the duration of progression-free survival. Interestingly, these genetic changes have been previously implicated as associated with outcome in natural history studies of melanoma, and preclinically, in response to treatment with BRAF inhibition, so we cannot discriminate if they are predictive or prognostic markers. Our data suggest that genetic analysis of *PTEN*, *CDKN2A*, and *CCND1* may be used to identify patients who should be considered for frontline combinatorial approaches, particularly using agents targeting pathways activated by aberrations in these genes. This study also emphasizes the continued importance of trials with associated biopsies on a large number of patients, so that we may gain insights into predictors of clinical outcome.

subtypes of melanomas (8, 9). The frequency of these genomic changes allows their study in conjunction with outcome upon treatment of melanoma.

Until recently, most systemic therapy options available for patients with advanced stage melanoma were ineffective, and the 5-year survival rate was less than 15%. In addition to immunotherapeutic agents, therapies directed at the MAPK signaling pathway have been developed, in particular targeted inhibition of the mutant V600E BRAF protein. Dabrafenib is a reversible ATP-competitive inhibitor that selectively inhibits mutant $BRAF^{V600E}$, with an IC_{50} (concentration required for 50% inhibition) 5-fold lower than for wild-type BRAF or CRAF (10). Treatment of BRAF-mutant metastatic melanoma with the RAF inhibitors dabrafenib or vemurafenib results in response rates of approximately 50% and significantly improved progression-free survival (PFS) and overall survival (OS) as compared with dacarbazine chemotherapy (11–14). The emergence of acquired resistance in the majority of patients, for which multiple mechanisms have been described, involving both reactivation of the MAPK signaling pathway and by-pass mechanisms, remains the greatest barrier to better clinical outcomes (15–22).

Preclinical studies have also identified several mechanisms of *de novo* or intrinsic resistance to BRAF inhibitors, including PTEN loss (alone or in conjunction with Rb1 loss), MET, and SRC activation (associated with amplification of *MET*, *CTNNB1*, and *CCND1*), activation of P70S6K and S6, and hepatocyte growth factor mediated MET expression (21–26). To improve our understanding of the clinical significance of these DNA-based aberrations implicated in intrinsic resistance, and other candidate genes previously

identified as aberrant in melanoma, we report here the molecular analysis of a large collection of human melanoma tumor samples from patients treated on the phase I clinical trial of the BRAF inhibitor dabrafenib (11).

Patients and Methods

Patients and clinical outcome

Melanoma tumor samples were collected from patients enrolled on the first-time-in-human BRF112680 phase I trial of dabrafenib (GSK2118436; clinical trial number NCT00880321) between May 27, 2009 and March 20, 2012, at 8 study centers in Australia and the United States (11). Samples were collected either at baseline ("pretreatment" and/or archival samples), "on-treatment," and when possible, at time of progression. Informed consent was obtained from all patients before the start of treatment and collection of tumor samples; the study complied with all local guidelines. Patients commenced on variable doses of dabrafenib (35–300 mg; Table 1); all were escalated to a total daily dose of $\geq$300 mg/day. The clinical outcome measures used in this study included the objective response and PFS using computed tomography and RECIST 1.0 as previously reported (11).

Tumor QC, DNA extraction

All samples were formalin-fixed and paraffin embedded and processed for hemotoxylin and eosin (H&E) staining and pathologist review of tumor content at the ACC Histology Core Facility by QCY. Samples with over 70% tumor content were processed for DNA extraction directly, whereas those with less than 70% tumor underwent H&E-guided macrodissection before DNA extraction. DNA was extracted using standard methods.

iPlex genotyping and PTEN sequencing

Genotyping conducted using a custom iPlex (Sequenom, Inc.) single nucleotide extension panel Genotyping was done at the Perelman School of Medicine Molecular Profiling Facility. Analysis of data was done using the iSeq software; we assessed the ratio of wildtype:mutant (T:A) nucleotide in $BRAF^{V600E}$ using the peak height chromatograms. Sanger sequencing of *PTEN* exons 1 to 9 was conducted using standard methods and published primers (27). Detailed methods are included in Supplementary Methods.

Copy number analysis

Multiplex ligation dependent probe amplification (MLPA) was used to detect copy number aberrations of genes located on chromosome 10q23 (MLPA kit P225-B2 PTEN; MRC-Holland). MLPA was conducted according to the manufacturer's instructions and analyzed with their software—MRC-Coffalyser Stand Alone Alpha Version 1.0.0.43 software. The fragments were analyzed on ABI 3130xl capillary sequencer using Genemapper software (Applied Biosystems, Inc.). Variation in peak height was evaluated by comparing each test sample to 3 normal controls present in the same experiment. Normalization

Table 1. Patient description

Patient characteristic		Total (n = 41)[a]
Dabrafenib starting dose	<150 mg twice a day	17 (41%)
	150 mg twice a day	15 (37%)
	>150 mg twice a day	9 (22%)
BRAF V600 mutation	V600E	34 (83%)
	V600K	7 (17%)
Distant metastasis	M1a/M1b	7 (17%)
	M1c	34 (83%)
ECOG performance	0	28 (68%)
	1	12 (29%)
	2	1 (2%)
LDH level	<1xULN	19 (46%)
	1–2xULN	13 (32%)
	>2xULN	7 (17%)
	Missing	2 (5%)
Number of prior systemic therapies	0	17 (41%)
	1	12 (29%)
	≥2	12 (29%)

[a]Only patients with baseline (pretreatment or archival) samples are included.

was done intrasample by dividing the peak area of each probe's amplification product by the total area of only the reference probes in this probe mix. Single regression for control and tumor data slope correction was conducted. Normal ratio limits were set at -0.70 and 1.2. This program identifies a peak as deleted when showing a ratio $<|0.7|$ and amplified when showing a ratio ≥ 1.2. The copy number of *PTEN* was measured in 17 samples using both MLPA and aCGH for cross-validation; all samples had the same copy number profiles.

Array-based comparative genomic hybridization was done using the Agilent SurePrint G3 Human CGH 1 × 1 M microarrays following manufacturer's instructions. Arrays were scanned using Agilent's High-Resolution C Scanner. Extracted data were analyzed using BioDiscovery's Nexus 6 copy-number software (Nexus Genomics Inc.). Copy number variation (CNV) was assessed using the CBS-like Rank Segmentation algorithm provided with Nexus 6; genes mapping was done to hg19, Feb 2009 build. Copy number gain was defined as log2 scale value ≥ 0.3 and loss as log2 scale value ≤ -0.3, with at least 3 contiguous single-nucleotide polymorphisms needed. Segments were particularly examined for the presence of high copy gains (log2 scale value ≥ 1.14) and homozygous loss (log2 scale value ≤ -1.1). In addition, only segments derived from >16 probes were included in subsequent analysis.

Chromosomal instability analysis

Characterizing cytogenetic instability was used as an alternative to analyzing specific, recurring copy number changes across the tumor set. To this end, copy number

alterations were first identified in the segmented data for each tumor and mapped to a specific chromosomal arm. Considering gains and losses separately, the total accumulation of copy number altered regions was calculated for each arm (i.e., total bases altered) and the fraction of the arm altered (total bases gained or lost/total size of arm).

Statistical analysis

PFS was compared in patients whose tumors had wild-type or nondeleted/mutant *PTEN* status versus those with deleted or mutant *PTEN* using the log-rank test and Kaplan–Meier analysis. Correlation between copy number values among 36 genes was assessed using Spearman's correlation analysis. Association between copy number values and PFS was evaluated using proportional hazards regression. In this analysis, $P < 0.05$ was considered statistically significant. Cytogenetic instability was analyzed between patients with pre- or early dose tissue. Comparisons were made using the median PFS of 24 weeks, with 12 patients having a PFS over 24 weeks and 11 patients with a PFS less than 24 weeks, using a *t* test.

Results

Description of patient population

A total of 91 samples were available from 77 patients. Eleven patients had multiple samples available. Twenty-seven samples were determined to have no tumor or in an amount too small to allow for adequate DNA extraction. We obtained *BRAF* mutational data on 57 melanoma tumor samples from 45 patients. Of these samples, 2 were on-treatment and 11 were progression samples, with the remaining 44 baseline (pretreatment or archival) samples. Patient characteristics for the 41 patients with baseline samples available are in Table 1.

Mutational information

In the 41 patients with baseline samples available, 6 had *BRAF*[V600K], 35 *BRAF*[V600E] mutations (Table 2). Two melanoma samples carrying the *BRAF*[V600E] mutation exhibited a T(wild-type):A(mutant) ratio favoring the mutant allele, one suggestive of amplification of that allele (patient 32, 1:4). Of the 7 *BRAF*[V600K] mutations observed, 2 samples showed T:A ratio favoring the mutant allele, suggestive of amplification of the mutant allele (patients 11, 19). The highest ratio favoring the mutant allele was seen in the archival sample from a patient also with a pretreatment sample, which had a ratio favoring the wild-type allele. Two patients with V600E mutations had additional concurrent mutations, one with *CTNNB1* (β-catenin) p.S45del and another with *MAP2K2* (MEK2) p.Q60P. The biopsy with the mutation in *MAP2K2* was taken at time of progression on trametinib (MEK inhibitor), before treatment with dabrafenib. Melanoma tumor samples, all taken from the same lesion, at multiple time points—archival, before treatment, and on-treatment with trametinib—were available for this patient and did not show the *MAP2K2* p.Q60P mutation,

Table 2. Mutational status using targeted assays and copy number analysis of PTEN

Patient no.	Sample type	BRAF	WT/mutant (T:A) ratios	PTEN mutation status and copy no.	Additional mutations
1	Pretreatment	V600E	1:1	WT/no CN[a]	
1	Progression	V600E	1:1	WT	
2	Progression	K601E	ND	Homo-Del[b]	
3	Pretreatment	V600E	1.5:1	WT	
4	Archival	V600K	1.5:1	Hemi-Del[c]	
4	Progression	V600K	2:1	WT	
5	Archival	V600E	2:1	AF	
6	Archival	V600E	1:1	Dup Ex 1[d]	
7	Archival	V600E	3:1	WT	
7	On-treatment	V600E	1:1	Hemi-Del	
7	Progression	V600E	3:1	WT	
8	Archival	V600E	1:1	Hemi-Del	
9	Archival	V600E	1:1	WT	*CTNNB1* S45del
10	Pretreatment	V600E	1.5:1	Homo-Del	
10	Progression	V600E	2:1	Homo-Del	
10	Progression	V600E	3:1	Hemi-Del	
11	Archival	V600K	1:3	Amplified	
11	Pretreatment	V600K	1.5:1	WT	
12	Archival	V600E	1.5:1	WT	
13	Archival	V600E	3:1	Amp/Del[e]	
14	Archival	V600E	1:1	WT/no CN	
14	Pretreatment	V600E	1.5:1	WT	
14	Progression	V600E	1:1	WT	
15	Archival	V600E	1.5:1	WT	
16	Archival	V600E	1:1	WT	
16	Pretreatment	V600E	2:1	Mutant	
17	Archival	V600E	1.5:1	WT/no CN	
18	Archival	V600K	1.5:1	WT	
19	Pretreatment	V600K	1:1.5	WT	
19	On-treatment	V600K	2:1	WT	
19	Progression	V600K	1:1.5	WT	
20	Archival	V600E	1:1	Hemi-Del	
21	Pretreatment	V600E	2:1	WT	
22	Archival	V600E	2:1	WT	
23	Archival	V600E	1:1	WT	
24	Archival	V600E	1:1	Hemi-Del	
25	Archival	V600E	1.5:1	WT	
26	Pretreatment	V600K	2:1	Homo-Del	
27	Archival	V600K	1:1	Dup Ex 1	
28	Archival	V600E	2:1	Hemi-Del	
29	Archival	V600E	2:1	Hemi-Del	
30	Archival	V600E	1.5:1	Amp/Del	
31	Archival	V600E	3:1	WT/no CN	
32	Archival	V600E	1:4	AF[f]	
33	Archival	V600E	1:2	Hemi-Del	
34	Progression	V600E	1:1	Homo-Del	
35	Progression	V600E	3:1	Homo-Del	
36	Archival	V600E	2:1	Hemi-Del	
37	Progression	WT	ND	WT	*NRAS* Q61K

(Continued on the following page)

Table 2. Mutational status using targeted assays and copy number analysis of PTEN (Cont'd)

Patient no.	Sample type	BRAF	WT/mutant (T:A) ratios	PTEN mutation status and copy no.	Additional mutations
38	Pretreatment	V600E	1:1	WT	*MEK2* Q60P
39	Archival	V600E	1:1	WT	
40	Archival	V600E	1:1	WT	
41	Archival	V600E	2.5:1	WT	
42	Archival	V600E	5:1	Hemi-Del	
43	Pretreatment	V600E	2:1	AF	
44	Archival	V600E	2:1	WT	
45	Archival	V600E	3:1	AF	

[a]WT/No CN, sequence wild-type, copy number could not be obtained.
[b]Homo-Del, homozygous deletion.
[c]Hemi-Del, hemizygous deletion.
[d]Dup Ex 1, duplication of exon 1.
[e]Amp/Del, duplication of exon 1, deletion of other exons.
[f]AF, assay failed.

suggesting it arose after treatment with trametinib (Infante; Nathanson; unpublished data). This patient had progressive disease as their best response to treatment with dabrafenib.

Data were available from 2 on-treatment and 11 progression samples from 10 patients (Table 2). Both of the on-treatment samples were from patients who also had progression samples. The 10 patients had melanomas carrying the following mutations; $BRAF^{V600E}$ (6), $BRAF^{V600K}$ (2), $BRAF^{K601E}$ (1), and $NRAS^{Q61K}$ (1). The progression sample with the *NRAS* mutation did not have a concurrent *BRAF* mutation, so it is possible that the patient had more than one primary melanoma, did not have BRAF mutant melanoma as no pretreatment sample was available for validation, or that the *BRAF* V600E mutation was present but undetectable based on the sensitivity of the assay. Six patients had matched pretreatment/archival and progression samples. In general, the ratio of mutant to wild-type allele was the same in both samples.

Association of baseline PTEN status with PFS

As we were particularly interested in the relationship of *PTEN* status to PFS upon treatment with dabrafenib, we evaluated it genetically with copy number analysis, using MLPA and/or aCGH, and sequencing of all exons. For this analysis, we focused on pretreatment and archival samples; data from the pretreatment sample was used preferentially for all analyses. Three patients had both archival and pretreatment samples. One patient had an archival sample with amplified PTEN; the pretreatment sample showed diploid PTEN. In one patient, a mutation in *PTEN* was observed in the pretreatment, but not archival sample. This mutation was the only one observed in *PTEN*, p.P95L, and has been previously reported in association with cancer (27–29). For four samples, we obtained only mutational, but not copy number data;

these samples were removed from further analysis. Thus, 34 patients had melanoma samples with PTEN data available for analysis (Table 2); patient characteristics are reported in Supplementary Table S1.

PTEN status was available for 11 progression and 2 on-treatment samples. Five progression samples had matched archival or pretreatment samples; in all but one case the copy number status was the same in both samples. Of note, homozygous deletion of PTEN was more frequently observed in progression tumor samples (4 of 10) than in archival or pretreatment samples (2 of 34), $P = 0.017$.

The relationship between best overall response (BOR) and PFS were evaluated. No association was seen between BOR and PTEN status with patients with melanomas having wild-type or nondeleted/nonmutant PTEN status having a response rate (CR+PR) of 43% [10/23; 95% confidence interval (CI), 21–65.9%] versus those with deleted or mutant PTEN of 36% (4/11; 95% CI, 3.4–69.3%), $P = 0.059$ (Fig. 1A). However, the patients with wild-type or nondeleted/nonmutant PTEN status had a longer PFS (32.1 weeks; 95% CI, 24.1–33) and those with deleted/mutant PTEN (18.3 weeks; 95% CI, 9.1–24.3; $P = 0.059$), $P = 0.059$ (Fig. 1B). As the *PTEN* status for 4 samples with exonic amplification could not be precisely determined to be either wild type or deleted, as potentially they could indicate rearrangements leading to PTEN loss, as in prostate cancer (30), they were removed for a secondary analysis. The PFS in the 18 patients with wild-type PTEN status was 32.1 weeks (95% CI, 24.1–39.4), longer than those with mutant/deleted PTEN, but this difference did not reach statistical significance ($P = 0.066$).

PTEN immunohistochemistry (IHC) was conducted on a subset ($n = 17$) of the samples with complete genetic data (Supplementary Table S2). The correlation between IHC data and genetic status was 75% (95% CI, 50.5–89.8);

Figure 1. Association with PTEN genetic status with response and progression-free survival upon treatment with dabrafenib. A, waterfall plot. One patient with stable disease was not included because tumor percent change was unknown. B, median PFS in patients with tumors with mutations or deletions of PTEN (red line) versus all others (black line).

presence/absence of staining data was not predictive of PFS in this small subset of patients (data not shown).

aCGH data

aCGH data were generated on 34 samples from 26 patients. Twenty-four archival and pretreatment samples were analyzed from 23 patients (1 patient had both archival and pretreatment samples). Eight patients had progression samples analyzed (2 for which we also had on-treatment samples). Three patients had both archival or pretreatment

samples and progression samples. Overall, the copy number analysis (Fig. 2A) was similar to that previously published for *BRAF* mutant cutaneous melanoma, with frequent copy number gains of 6p, 7q, and 22q, and frequent losses of 6q, 9p, and 10q (31–34). We also examined the overall genomic profile of pretreatment melanomas in relationship to PFS (Fig. 2B), BOR (Supplementary Fig. S1), and $BRAF^{V600E}$ versus $BRAF^{V600K}$ mutation status (Supplementary Fig. S2). The percentage of individual chromosome arms and total fraction of the genome that was altered

Figure 2. Array-based comparative genomic hybridization analysis of melanoma samples.

in patients with PFS > 24 weeks ($n = 12$) was compared to those with PFS ≤ 24 weeks ($n = 11$). Although the overall fraction of the genome gained or lost did not significantly differ between groups ($P = 0.19$ and 0.11, respectively), there were some notable qualitative differences. Most notably, when considering large alterations defined as those encompassing >25% of the size of a chromosomal arm (indicative of broad instability), gains of 6p seemed more frequent in the patients showing >24 versus ≤24 week PFS (58% vs. 27%, respectively). Similarly, large losses of 11q seemed more frequent in those patients with PFS >24 versus ≤24 weeks (33% vs. 9% of patients, respectively). Conversely, losses of 9p (25% vs. 55%), and 4q (0% vs. 27%) were qualitatively more frequent in those with shorter PFS. Although none of these differences achieved statistical significance ($P > 0.05$ in all cases), the overall rarity of such large genomic changes could suggest relationships with response in a subset of patients.

Specific genes from aCGH data

We selected 36 genes (Supplementary Table S3) implicated in melanoma pathogenesis for CNV characterization. A correlation analysis between copy number gains and losses of various genes, both positive and negative (i.e., gain–gain, gain–loss) was done, and is shown in Supplementary Table S4. Correlation of CNV results to PFS showed that copy gain of *CCND1* ($P = 0.009$) and loss of *CDKN2A* ($P = 0.012$) were independently predictive of shorter PFS. For visualization purposes of the association between copy number and outcome, the samples were divided by median copy number and Kaplan–Meier curves for PFS were generated (Fig. 3A and B). For *CCND1*, patients whose tumors had greater than the median copy number ($n = 11$) had a median PFS of 27 weeks (95% CI, 15–32 weeks), which was shorter (HR = 2.22) than those with a lower copy number ($n = 12$, median PFS 33 weeks, 95% CI, 24–45 weeks).

Patients with less than median copy number of *CDKN2A* ($n = 11$) had a median PFS of 25 weeks (95% CI, 17–32 weeks), whereas patients with a higher copy number had a median PFS of 31 weeks (95% CI, 15–56 weeks, HR = 0.59). Of note, neither copy number of *CDKN2A* nor *CCND1* was associated with BOR. High-level amplification of the BRAF locus (>5 copies) was not observed in these 25 patients, and *BRAF* copy number did not significantly correlate with BOR or PFS (Fig. 3C).

Discussion

To the authors' knowledge, this study represents the largest genetic and genomics-based examination of human melanoma tissue from patients treated with BRAF inhibitors, specifically patients treated with dabrafenib on the phase I/II trial (11), to identify correlates associated with response. We focused on the genes encoding the proteins of the MAPK (Ras/Raf/MEK/ERK) and PI3K/Akt pathways, as they are the principal signaling pathways shown to be crucial in melanoma initiation and progression (6, 35). Cell-cycle regulatory proteins, such as p16, CKD4, and cyclin D1, also have been shown to play important roles in melanoma, and those genetic and genomic aberrations involving these also were specifically interrogated (36–38). We also took a more comprehensive unbiased approach, using aCGH, to identify additional genomic aberrations which might be associated with response.

All baseline (pretreatment and archival) samples had confirmed V600 mutations in *BRAF*, a study eligibility requirement. High-level copy (over 5) amplification of *BRAF* was not observed in any of the samples. A few samples showed relative increases in the ratio of the *BRAF* V600 mutant to wild-type allele, either in the pretreatment samples, or at the time of progression; most samples showed equivalent or increased wild-type allele. Of note, 2 of the 3 samples from patients with progressive disease as best

Figure 3. Association between gene copy number and outcome. For visualization of the association between copy number and outcome, the samples were divided by median copy number and Kaplan–Meier curves for PFS were generated (A) *CCND1*, (B) *CDKN2A*, and (C) BRAF copy gain and correlation with PFS, response, and time of sample collection (A, archival; P, pretreatment; S, on-treatment; G, progression).

response had copy number gain of *BRAF*, however 1 was from a progression sample without a matching pretreatment specimen. Although our numbers are too small to draw any definitive conclusion from, they are consistent with prior findings suggesting that increased copy number of *BRAF* is associated with progressive disease in some

patients who are treated with BRAF or MEK inhibitors (15, 39). Importantly, preclinical studies suggest that this mechanism of resistance may potentially be overcome with increased doses of selective BRAF inhibitors (15).

We conducted detailed analysis of PTEN genetic status in association with response to BRAF inhibition, as several preclinical studies have suggested that PTEN loss contributes to intrinsic BRAF resistance (23, 24). Our data suggest that PTEN loss is associated with a shorter PFS in patients treated with BRAF inhibitors, although is not predictive of best overall clinical response. This finding is not unexpected, as degree of response is not necessarily correlated with duration with targeted agents. Interestingly, PFS correlated with OS in the phase 3 study of vemurafenib, the only study able to use OS as a primary endpoint (40). It has been suggested that PTEN loss, as measured through IHC, is a negative prognostic factor for melanoma, independent of BRAF inhibition (41, 42). PTEN loss also is found more frequently in brain than lung or liver metastases, which are associated with worse prognosis (35). However, genetic analysis of PTEN status has not been previously assessed as a predictive or prognostic marker in melanoma, and has not been correlated with immunochemistry analyses. Although our data suggest that analyses using genetic methods may ultimately be better predictors of outcome than immunochemistry measurements, analyses of larger cohorts of patients with parallel genetics and proteomic analysis are needed to make definitive conclusions.

Copy number analysis of 36 genes previously observed to be altered in melanoma was conducted on samples from 23 dabrafenib-treated patients. Among those genes, lower copy number of CDKN2A and higher copy number of CCND1 were significantly associated with shorter PFS. The regions containing these genes also were implicated in our overall (unbiased) analysis of aCGH data, as CCND1 is located on 11q and CDKNA on 9p. Both deletion/loss of CDKN2A (p16) and amplification/overexpression of CCND1 (cyclin D1) previously have been implicated as poor prognostic markers in melanoma (43–47). Thus, these genetic changes may function as either prognostic or predictive markers in response to BRAF inhibition. Amplification of CCND1 also has been associated with intrinsic resistance to BRAF inhibition in preclinical studies (25, 48). Other genes which have been implicated in intrinsic resistance to BRAF inhibition, including Rb1 loss, MET and SRC amplification, did not emerge as associated with PFS in our analysis (24, 25).

Although this study contains a large set of melanoma tissue samples from patients treated with dabrafenib, samples were not available from all patients enrolled in the clinical trial, potentially limiting the generalizability of our results. However, the characteristics of the patients included in the correlative studies, as reviewed in Table 1, did not differ from those on the trial as a whole (data not shown). We were not able to determine whether the genetic alterations identified as correlates of clinical outcome were predictive, prognostic or both, and prior clinical and preclinical data support both interpretations of the data. Some tissue samples collected at progression lacked a paired baseline specimen, limiting our interpretation of the genetic and genomic findings in the progression samples. Several studies have showed intratumoral heterogeneity using massively parallel sequencing (49, 50). Based on our own studies using massively parallel sequencing in a similar sample set (data not shown), low-level point mutations (<5–10% allele frequency), such as in NRAS, could have been missed. However, copy number changes (other than high-level amplification) are more difficult to interpret without matched germline samples using massively parallel sequencing, particularly for capture-based methods. Thus, it is less likely that massively parallel sequencing would have provided greatly improved sensitivity in this context. Finally, as we mainly focused on known genetic alterations and genomic aberrations associated with melanoma, it is possible that we did not identify novel predictors of clinical outcome in this dataset. Of note, however, our unbiased analysis of copy number also pointed towards CDKN2A (9p) and CCND1 (11q).

In summary, we identified PTEN loss, CDKN2A deletion, and CCND1 amplification as associated with decreased PFS upon treatment with dabrafenib. An exploratory analysis (data not shown) showed that carriage of two genomic alterations, or all three together, was associated with a trend toward worsening PFS. Although the interpretation of this analysis was limited by the small number of patients in each group, this approach should be considered for larger sample sets in the future. Ultimately, if validated in future patients, genetic analysis of PTEN, CDKN2A, and CCND1 may be used to identify patients who should be considered for frontline combinatorial approaches, particularly using agents that are activated by aberrations in these genes. Thus, these data suggest where potential combination therapies in conjunction with dabrafenib might be most effectively targeted. These studies also emphasize the continued importance of trials with associated biopsies on a large number of patients, so that we may gain insights into predictors of clinical outcome.

Disclaimer

Authors' Contributions

Conception and design: K.L. Nathanson, A.-M. Martin, S. O'Day, B. Ma, C. M. Curtis, P.F. Lebowitz, R.F. Kefford

Development of methodology: K.L. Nathanson, A.-M. Martin, K. D'Andrea, J.R. Infante, R.F. Kefford

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): K.L. Nathanson, R. Letrero, K. D'Andrea, S. O'Day, J.R. Infante, G.S. Falchook, H.-T. Arkenau, M. Millward, M.P. Brown, A. Pavlick, M.A. Davies, R.F. Kefford, G.V. Long

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): K.L. Nathanson, A.-M. Martin, B. Wubbenhorst, J. Greshock, J.R. Infante, G.S. Falchook, H.-T. Arkenau, A. Pavlick, M.A. Davies, B. Ma, R. Gagnon, C.M. Curtis, R.F. Kefford, G.V. Long

Writing, review, and/or revision of the manuscript: K.L. Nathanson, A.-M. Martin, J. Greshock, S. O'Day, J.R. Infante, G.S. Falchook, H.-T. Arkenau, M. Millward, M.P. Brown, A. Pavlick, M.A. Davies, R. Gagnon, C.M. Curtis, P. F. Lebowitz, R.F. Kefford, G.V. Long

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): K.L. Nathanson, K. D'Andrea

Study supervision: K.L. Nathanson, A.-M. Martin, J.R. Infante, M.P. Brown, R.F. Kefford, G.V. Long

References

1. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Altekruse SF, et al. SEER cancer statistics review, 1975–2009 (vintage 2009 populations). Based on November 2011 SEER data submission, posted to the SEER web site, 2012. Bethesda, MD: National Cancer Institute; 2012.
2. Pleasance ED, Cheetham RK, Stephens PJ, McBride DJ, Humphray SJ, Greenman CD, et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 2010;463:191–6.
3. Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP, et al. A landscape of driver mutations in melanoma. Cell 2012;150: 251–63.
4. Jakob JA, Bassett RL Jr., Ng CS, Curry JL, Joseph RW, Alvarado GC, et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 2011;118:4014–23
5. Long GV, Menzies AM, Nagrial AM, Haydu LE, Hamilton AL, Mann GJ, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 2011;29:1239–46.
6. Fecher LA, Amaravadi RK, Flaherty KT. The MAPK pathway in melanoma. Curr Opin Oncol 2008;20:183–9.
7. Lovly CM, Dahlman KB, Fohn LE, Su Z, Dias-Santagata D, Hicks DJ, et al. Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials. PLoS One 2012;7: e35309.
8. Gast A, Scherer D, Chen B, Bloethner S, Melchert S, Sucker A, et al. Somatic alterations in the melanoma genome: a high-resolution array-based comparative genomic hybridization study. Genes Chromosomes Cancer 2010;49:733–45.
9. Krauthammer M, Kong Y, Ha BH, Evans P, Bacchiocchi A, McCusker JP, et al. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet 2012;44:1006–14.
10. GlaxoSmithKline. BRF113683 clinical study report. 2012.
11. Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau TH, Brown MP, et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 2012;379:1893–901.
12. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012;380:358–65.
13. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363:809–19.
14. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507–16.
15. Shi H, Moriceau G, Kong X, Lee MK, Lee H, Koya RC, et al. Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nature Commun 2012;3:724.
16. Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 2011;480:387–90.
17. Wagle N, Emery C, Berger MF, Davis MJ, Sawyer A, Pochanard P, et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol 2011;29:3085–96.
18. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010;468:973–7.
19. Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010;468:968–72.
20. Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Cipolla AK, et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 2010;18:683–95.
21. Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J, et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012;487:500–4.
22. Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 2012;487:505–9.
23. Paraiso KH, Xiang Y, Rebecca VW, Abel EV, Chen YA, Munko AC, et al. PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res 2011;71:2750–60.
24. Xing F, Persaud Y, Pratilas CA, Taylor BS, Janakiraman M, She QB, et al. Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF. Oncogene 2012;31:446–57.
25. Vergani E, Vallacchi V, Frigerio S, Deho P, Mondellini P, Perego P, et al. Identification of MET and SRC activation in melanoma cell lines showing primary resistance to PLX4032. Neoplasia (New York, NY) 2011;13:1132–42.
26. Deng W, Gopal YN, Scott A, Chen G, Woodman SE, Davies MA. Role and therapeutic potential of PI3K-mTOR signaling in *de novo*

resistance to BRAF inhibition. Pigment Cell Melanoma Res 2012;25: 248–58.

27. Levine RL, Cargile CB, Blazes MS, van Rees B, Kurman RJ, Ellenson LH. PTEN mutations and microsatellite instability in complex atypical hyperplasia, a precursor lesion to uterine endometrioid carcinoma. Cancer Res 1998;58:3254–8.

28. Tashiro H, Blazes MS, Wu R, Cho KR, Bose S, Wang SI, et al. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res 1997;57:3935–40.

29. Yaginuma Y, Yamashita T, Ishiya T, Morizaki A, Katoh Y, Takahashi T, et al. Abnormal structure and expression of PTEN/MMAC1 gene in human uterine cancers. Mol Carcinog 2000;27:110–6.

30. Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, Sivachenko AY, et al. The genomic complexity of primary human prostate cancer. Nature 2011;470:214–20.

31. Greshock J, Nathanson K, Medina A, Ward MR, Herlyn M, Weber BL, et al. Distinct patterns of DNA copy number alterations associate with BRAF mutations in melanomas and melanoma-derived cell lines. Genes Chromosomes Cancer 2009;48:419–28.

32. Jonsson G, Dahl C, Staaf J, Sandberg T, Bendahl PO, Ringner M, et al. Genomic profiling of malignant melanoma using tiling-resolution array CGH. Oncogene 2007;26:4738–48.

33. Stark M, Hayward N. Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays. Cancer Res 2007;67:2632–42.

34. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005;353:2135–47.

35. Davies MA, Stemke-Hale K, Lin E, Tellez C, Deng W, Gopal YN, et al. Integrated molecular and clinical analysis of AKT activation in metastatic melanoma. Clin Cancer Res 2009;15:7538–46.

36. Tsao H, Chin L, Garraway LA, Fisher DE. Melanoma: from mutations to medicine. Genes Dev 2012;26:1131–55.

37. Hussussian CJ, Struewing JP, Goldstein AM, Higgins PA, Ally DS, Sheahan MD, et al. Germline p16 mutations in familial melanoma. Nat Genet 1994;8:15–21.

38. Zuo L, Weger J, Yang Q, Goldstein AM, Tucker MA, Walker GJ, et al. Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet 1996;12:97–9.

39. Corcoran RB, Dias-Santagata D, Bergethon K, Iafrate AJ, Settleman J, Engelman JA. BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. Sci Signal 2010;3:ra84.

40. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012;366:707–14.

41. Meyer S, Fuchs TJ, Bosserhoff AK, Hofstadter F, Pauer A, Roth V, et al. A seven-marker signature and clinical outcome in malignant melanoma: a large-scale tissue-microarray study with two independent patient cohorts. PLoS One 2012;7:e38222.

42. Mikhail M, Velazquez E, Shapiro R, Berman R, Pavlick A, Sorhaindo L, et al. PTEN expression in melanoma: relationship with patient survival, Bcl-2 expression, and proliferation. Clin Cancer Res 2005;11:5153–7.

43. Gammon B, Ali L, Guitart J, Gerami P. Homogeneous staining regions for cyclin D1, a marker of poor prognosis in malignant melanoma. Am J Dermatopathol 2012;34:487–90.

44. Gerami P, Jewell SS, Pouryazdanparast P, Wayne JD, Haghighat Z, Busam KJ, et al. Copy number gains in 11q13 and 8q24 [corrected] are highly linked to prognosis in cutaneous malignant melanoma. J Mol Diagn 2011;13:352–8.

45. Karim RZ, Li W, Sanki A, Colman MH, Yang YH, Thompson JF, et al. Reduced p16 and increased cyclin D1 and pRb expression are correlated with progression in cutaneous melanocytic tumors. Int J Surg Pathol 2009;17:361–7.

46. Conway C, Beswick S, Elliott F, Chang YM, Randerson-Moor J, Harland M, et al. Deletion at chromosome arm 9p in relation to BRAF/NRAS mutations and prognostic significance for primary melanoma. Genes Chromosomes Cancer 2010;49:425–38.

47. Gallagher SJ, Thompson JF, Indsto J, Scurr LL, Lett M, Gao BF, et al. p16INK4a expression and absence of activated B-RAF are independent predictors of chemosensitivity in melanoma tumors. Neoplasia (New York, NY) 2008;10:1231–9.

48. Smalley KS, Lioni M, Dalla Palma M, Xiao M, Desai B, Egyhazi S, et al. Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF-V600E mutated melanomas. Mol Cancer Ther 2008;7: 2876–83.

49. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366:883–92.

50. Navin N, Kendall J, Troge J, Andrews P, Rodgers L, McIndoo J, et al. Tumour evolution inferred by single-cell sequencing. Nature 2011; 472:90–4.

Clinical Cancer Research

AACR American Association for Cancer Research

Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436)

Katherine L. Nathanson, Anne-Marie Martin, Bradley Wubbenhorst, et al.

Updated version	Access the most recent version of this article at: doi:10.1158/1078-0432.CCR-13-0827
Supplementary Material	Access the most recent supplemental material at: http://clincancerres.aacrjournals.org/content/suppl/2013/07/08/1078-0432.CCR-13-0827.DC1

Cited articles	This article cites 48 articles, 11 of which you can access for free at: http://clincancerres.aacrjournals.org/content/19/17/4868.full#ref-list-1
Citing articles	This article has been cited by 22 HighWire-hosted articles. Access the articles at: http://clincancerres.aacrjournals.org/content/19/17/4868.full#related-urls

E-mail alerts	Sign up to receive free email-alerts related to this article or journal.
Reprints and Subscriptions	To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.
Permissions	To request permission to re-use all or part of this article, use this link http://clincancerres.aacrjournals.org/content/19/17/4868. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.